Francesco Calzaferri

Dr. Francesco Calzaferri

Institut des Biomolécules Max Mousseron (IBMM - UMR5247, CNRS)
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2020 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
FCFrancesco Calzaferri
Francesco Calzaferri
CRCristina Ruiz‐Ruiz
Cristina Ruiz‐Ruiz
ADAntonio M. G. de Diego
Antonio M. G. de Diego
RPRicardo de Pascual
Ricardo de Pascual
IMIago Méndez‐López
Iago Méndez‐López
ADANTONIO M GARCIA DE DIEGO
ANTONIO M GARCIA DE DIEGO

27 December 2021 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
EBEdward Beamer
Edward Beamer
JMJames Morgan
James Morgan
MAMariana Alves
Mariana Alves
AMAida Menéndez Méndez
Aida Menéndez Méndez
GMGareth Morris
Gareth Morris
Tobias Engel EngelTobias Engel Engel
Tobias Engel Engel

9 February 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FCFrancesco Calzaferri
Francesco Calzaferri
PNPaloma Narros-Fernández
Paloma Narros-Fernández
RPRicardo de Pascual
Ricardo de Pascual
ADAntonio M.G. de Diego
Antonio M.G. de Diego
ANAnnette Nicke
Annette Nicke
Cristobal De Los RiosCristobal De Los Rios
Cristobal De Los Rios
The ATP-gated P2X7 purinergic receptor (P2X7) is involved in the pathogenesis of many neurodegenerative diseases (NDDs). Several P2X7 antagonists have been developed, though none of them reached clinical trials for this indication. In this work, we designed and synthesized novel blood–brain barrier (BBB)-permeable derivatives as potential P2X7 antagonists. They comprise purine or xanthine cores linked to an aryl group through different short spacers. Compounds were tested in YO-PRO-1 uptake assays and intracellular calcium dynamics in a human P2X7-expressing HEK293 cell line, two-electrode voltage-clamp recordings in Xenopus laevis oocytes, and in interleukin 1β release assays in mouse peritoneal macrophages. BBB permeability was assessed by parallel artificial membrane permeability assays and P-glycoprotein ATPase activity. Dichloroarylpurinylethanones featured a certain P2X7 blockade, being compound 6 (2-(6-chloro-9H-purin-9-yl)-1-(2,4-dichlorophenyl)ethan-1-one), named ITH15004, the most potent, selective, and BBB-permeable antagonist. Compound 6 can be considered as a first non-nucleotide purine hit for future drug optimizations.

12 June 2020 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
CRCristina Ruiz-Ruiz
Cristina Ruiz-Ruiz
FCFrancesco Calzaferri
Francesco Calzaferri
ADANTONIO M GARCIA DE DIEGO
ANTONIO M GARCIA DE DIEGO
This review focuses on the purinergic ionotropic receptor P2X7 (P2X7R) as a potential target for developing drugs that delay the onset and/or disease progression in patients with amyotrophic lateral sclerosis (ALS). Description of clinical and genetic ALS features is followed by an analysis of advantages and drawbacks of transgenic mouse models of disease based on mutations in a bunch of proteins, particularly Cu/Zn superoxide dismutase (SOD1), TAR-DNA binding protein-43 (TDP-43), Fused in Sarcoma/Translocated in Sarcoma (FUS), and Chromosome 9 open reading frame 72 (C9orf72). Though of limited value, these models are however critical to study the proof of concept of new compounds, before reaching clinical trials. The authors also provide a description of ALS pathogenesis including protein aggregation, calcium-dependent excitotoxicity, dysfunction of calcium-binding proteins, ultrastructural mitochondrial alterations, disruption of mitochondrial calcium handling, and overproduction of reactive oxygen species (ROS). Understanding disease pathogenic pathways may ease the identification of new drug targets. Subsequently, neuroinflammation linked with P2X7Rs in ALS pathogenesis is described in order to understand the rationale of placing the use of P2X7R antagonists as a new therapeutic pharmacological approach to ALS. This is the basis for the hypothesis that a P2X7R blocker could mitigate the neuroinflammatory state, indirectly leading to neuroprotection and higher motoneuron survival in ALS patients.

2 February 2023 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
PMPaula Mut-Arbona
Paula Mut-Arbona
LHLumei Huang
Lumei Huang
MBMária Baranyi
Mária Baranyi
PTPál Tod
Pál Tod
AIAndrás Iring
András Iring
BSBeáta Sperlágh
Beáta Sperlágh
At high levels, extracellular ATP operates as a “danger” molecule under pathologic conditions through purinergic receptors, including the ionotropic P2X7 receptor (P2X7R). Its endogenous activation is associated with neurodevelopmental disorders; however, its function during early embryonic stages remains largely unclear. Our objective was to determine the role of P2X7R in the regulation of neuronal outgrowth. For this purpose, we performed Sholl analysis of dendritic branches on primary hippocampal neurons and in acute hippocampal slices from WT mice and mice with genetic deficiency or pharmacological blockade of P2X7R. Because abnormal dendritic branching is a hallmark of certain neurodevelopmental disorders, such as schizophrenia, a model of maternal immune activation (MIA)-induced schizophrenia, was used for further morphologic investigations. Subsequently, we studied MIA-induced behavioral deficits in young adult mice females and males. Genetic deficiency or pharmacological blockade of P2X7R led to branching deficits under physiological conditions. Moreover, pathologic activation of the receptor led to deficits in dendritic outgrowth on primary neurons from WT mice but not those from P2X7R KO mice exposed to MIA. Likewise, only MIA-exposed WT mice displayed schizophrenia-like behavioral and cognitive deficits. Therefore, we conclude that P2X7R has different roles in the development of hippocampal dendritic arborization under physiological and pathologic conditions.SIGNIFICANCE STATEMENTOur main finding is a novel role for P2X7R in neuronal branching in the early stages of development under physiological conditions. We show how a decrease in the expression of P2X7R during brain development causes the receptor to play pathologic roles in adulthood. Moreover, we studied a neurodevelopmental model of schizophrenia and found that, at higher ATP concentrations, endogenous activation of P2X7R is necessary and sufficient for the development of positive and cognitive symptoms.

26 May 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FCFrancesco Calzaferri
Francesco Calzaferri
HDHiba Daher
Hiba Daher
JGJulie Gilbert
Julie Gilbert
YYYinshan Yang
Yinshan Yang
MTMarine Tauziet
Marine Tauziet
MLMarie Lopez
Marie Lopez